Clinical Study
A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis
Table 3
Cox proportional hazard model for relapse in Tac group.
| Parameter | Multivariate analysis (Cox proportional hazard model) | HR | 95% CI | value |
| Sex | | | 0.79 | Male | 1 | | | Female | 1.14 | 0.41–3.25 | | Age at start of the treatment (y) | | | 0.058 | 20 | 1 | | | 20 | 11.6 | 0.92–156.1 | | Disease duration at the treatment (y) | | | 0.68 | 5 | 1 | | | 5 | 1.35 | 0.33–6.54 | | Disease extension | | | 0.59 | Left-sided colitis | 1 | | | Extensive colitis | 1.34 | 0.47–4.38 | | Response to corticosteroids | | | 0.97 | Dependence | 1 | | | Refractory | 0.98 | 0.17–4.48 | | Concomitant use of thiopurine | | | 0.027 | Yes | 1 | | | No | 6.83 | 1.27–32.4 | | Continuing use of Tac beyond 3 months | | | 0.018 | Yes | 1 | | | No | 8.33 × 108 | 1.56–1.8 × 10290 | |
|
|
HR, hazard ratio; CI, confidence interval.
|